Skip to search formSkip to main contentSkip to account menu

Lirilumab

Known as: IPH2102 
A fully humanized monoclonal antibody against killer-cell immunoglobulin-like receptors (KIR), with potential antineoplastic activity. Upon… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Mechanisms of resistance to immune‐modulating cancer treatments are poorly understood. Using a novel cohort of patients with head… 
Highly Cited
2018
Highly Cited
2018
Purpose Anti-KIR monoclonal antibodies (mAbs) can enhance the antitumor responses of natural killer (NK) cells. We evaluated the… 
Review
2017
Review
2017
Background Inhibitory Killer Immunoglobulin-like Receptors (KIR) negatively regulate Natural Killer (NK) cell-mediated killing of… 
2017
2017
e18505Background: Lack of KIR-HLA class I interactions has been associated with NK-mediated antitumor efficacy in AML patients… 
2016
2016
### O1 Combinatorial CD8+ and PD-L1+ cell densities correlate with response and improved survival in non-small cell lung cancer… 
Highly Cited
2015
Highly Cited
2015
Despite recent treatment improvements, multiple myeloma remains an incurable disease. Since antibody-dependent cell-mediated… 
2015
2015
3065 Background: Inhibitory Killer Immunoglobulin-like receptors (KIRs) negatively regulate the killing, by NK cells, of tumors… 
Highly Cited
2014
Highly Cited
2014
Natural killer (NK) cells mediate antilymphoma activity by spontaneous cytotoxicity and antibody-dependent cell-mediated… 
Review
2013
Review
2013
Natural killer (NK) cells are critical innate immune lymphocytes capable of destroying virally infected or cancerous cells… 
2013
2013
Natural Killer cells (NK cells) are lymphocytes able to recognize and kill tumors for which the expression of Major…